Dashboard
Manage Tickers

VRDN


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

rbc-capital-maintains-outperform-on-viridian-therapeutics-raises-price-target-to-44
RBC Capital Maintains Outperform on Viridi...
09/13/2024 13:54:39

RBC Capital analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price targe...

goldman-sachs-maintains-buy-on-viridian-therapeutics-raises-price-target-to-31
Goldman Sachs Maintains Buy on Viridian Th...
09/12/2024 15:45:44

Goldman Sachs analyst Richard Law maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from ...

reported-earlier-viridian-therapeutics-prices-225m-upsized-public-offering-10666600-common-shares-at-1875share-and-preferred-stock
Reported Earlier, Viridian Therapeutics Pr...
09/12/2024 06:53:21

Viridian is selling a total of 10,666,600 shares of common stock at a public offering price of $18.75 per share and 20,000 shar...

needham-maintains-buy-on-viridian-therapeutics-raises-price-target-to-38
Needham Maintains Buy on Viridian Therapeu...
09/11/2024 11:06:33

Needham analyst Serge Belanger maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $30...

viridian-therapeutics-announces-150m-proposed-underwritten-public-offering-of-common-stock-and-preferred-stock
Viridian Therapeutics Announces $150M Prop...
09/10/2024 20:01:49

critical-insights-from-viridian-therapeutics-analyst-ratings-what-you-need-to-know
Critical Insights From Viridian Therapeuti...
09/10/2024 20:00:36

hc-wainwright--co-reiterates-buy-on-viridian-therapeutics-maintains-27-price-target
HC Wainwright & Co. Reiterates Buy on Viri...
09/10/2024 17:43:16

HC Wainwright & Co. analyst Douglas Tsao reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $27 pri...

btig-maintains-buy-on-viridian-therapeutics-raises-price-target-to-56
BTIG Maintains Buy on Viridian Therapeutic...
09/10/2024 15:47:29

BTIG analyst Julian Harrison maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $46 t...

calavo-growers-posts-better-than-expected-earnings-joins-tesla-oracle-mission-produce-and-other-big-stocks-moving-higher-on-tuesday
Calavo Growers Posts Better-Than-Expected ...
09/10/2024 14:07:31

viridian-therapeutics-discloses-exciting-data-from-experimental-thyroid-eye-disease-candidate-says-data-met-high-bars-for-efficacy-safety
Viridian Therapeutics Discloses 'Exciting'...
09/10/2024 13:14:50

Viridian Therapeutics announced promising topline data from the THRIVE phase 3 trial of VRDN-001 (veligrotug) for active thyroi...

Core News & Articles
Market-Moving News for September 10th
09/10/2024 11:52:43

ORCL: 9% | Oracle shares are trading higher following better-than-expected Q1 financial results. JMP Securities upgraded the st...

viridian-therapeutics-says-veligrotug-vrdn-001-achieved-all-primary-and-secondary-endpoints-in-thrive-phase-3-trial
Viridian Therapeutics Says Veligrotug (VRD...
09/10/2024 11:07:49

Cash, cash equivalents, and short-term investments of $571.4 million as of June 30, 2024; provides cash runway into the second ...

why-oracle-shares-are-trading-higher-by-around-9-here-are-20-stocks-moving-premarket
Why Oracle Shares Are Trading Higher By Ar...
09/10/2024 10:41:15

viridian-therapeutics-to-host-webcast-vrdn-001-phase-3-thrive-topline-results-on-sept-10-2024
Viridian Therapeutics To Host Webcast VRDN...
09/09/2024 20:03:39

- THRIVE global phase 3 clinical trial evaluated efficacy and safety of VRDN-001 in patients with active thyroid eye disease (T...

needham-reiterates-buy-on-viridian-therapeutics-maintains-30-price-target
Needham Reiterates Buy on Viridian Therape...
08/30/2024 15:25:25

Needham analyst Serge Belanger reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $30 price target.

rbc-capital-reiterates-outperform-on-viridian-therapeutics-maintains-35-price-target
RBC Capital Reiterates Outperform on Virid...
08/28/2024 12:53:24

RBC Capital analyst Gregory Renza reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and maintains $35 price t...

decoding-6-analyst-evaluations-for-viridian-therapeutics
Decoding 6 Analyst Evaluations For Viridia...
08/15/2024 12:01:38

hc-wainwright--co-reiterates-buy-on-viridian-therapeutics-maintains-27-price-target
HC Wainwright & Co. Reiterates Buy on Viri...
08/15/2024 10:23:47

HC Wainwright & Co. analyst Douglas Tsao reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $27 pri...

oppenheimer-reiterates-outperform-on-viridian-therapeutics-lowers-price-target-to-28
Oppenheimer Reiterates Outperform on Virid...
08/12/2024 13:48:18

Oppenheimer analyst Leland Gershell reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and lowers the price ta...

viridian-therapeutics-q2-2024-adj-eps-102-misses-089-estimate-sales-7200k-miss-8615k-estimate
Viridian Therapeutics Q2 2024 Adj EPS $(1....
08/08/2024 12:29:48

Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(1.02) per share which missed the analyst consensus estimate ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION